Diverticulitis Disease - Global Strategic Business Report

The global market for Diverticulitis Disease was estimated at US$1.8 Billion in 2024 and is projected to reach US$2.6 Billion by 2030, growing at a CAGR of 6.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Diverticulitis Disease market.

Global Diverticulitis Disease Market - Key Trends & Drivers Summarized

Why Is Diverticulitis Garnering Growing Medical Attention Worldwide?

The global diverticulitis disease market is experiencing heightened interest due to the increasing prevalence of gastrointestinal disorders and the rising demand for effective treatment solutions. Diverticulitis, a condition characterized by inflammation or infection of diverticula in the digestive tract, is becoming more common, particularly in aging populations and in regions adopting Western dietary habits. Sedentary lifestyles, low-fiber diets, and obesity are significant contributing factors to the rise in incidence. As healthcare systems globally improve diagnostic capabilities, more cases are being identified at earlier stages, leading to a broader patient base in need of medical intervention. The clinical spectrum of the disease from uncomplicated cases to those requiring surgical procedures has expanded the therapeutic landscape, encompassing antibiotics, anti-inflammatory medications, dietary modifications, and increasingly, advanced surgical treatments. The growing burden on healthcare resources, coupled with an aging demographic, has positioned diverticulitis as a condition of both clinical urgency and commercial opportunity, especially in developed nations.

How Are Diagnostics and Treatments Evolving in Response to Changing Demographics?

Rapid advancements in imaging technologies and diagnostic procedures are enabling more accurate detection and classification of diverticulitis, which is crucial for targeted treatment. High-resolution CT scans and colonoscopies are now standard diagnostic tools, allowing for differentiation between simple and complicated cases. On the treatment front, there is a significant shift toward non-invasive and outpatient management strategies, especially for mild to moderate cases. Antibiotic stewardship programs are encouraging physicians to limit unnecessary antibiotic use, leading to refined treatment protocols. Simultaneously, research is ongoing into novel anti-inflammatory agents and biologics that could provide targeted relief with fewer side effects. In severe cases, minimally invasive surgeries like laparoscopic resection are becoming more common, reducing hospital stays and recovery times. Nutritional therapy and fiber supplementation also play essential roles in recurrence prevention, and these aspects are being increasingly integrated into patient management plans. This confluence of better diagnostics and diversified treatments is reshaping the standard of care for diverticulitis worldwide.

Which Populations and Markets Are Driving Demand for Diverticulitis Solutions?

North America and Europe are the most mature markets for diverticulitis treatment, primarily due to high disease prevalence, established healthcare infrastructure, and strong awareness among both patients and practitioners. The United States, in particular, exhibits the highest incidence rates, attributed to dietary patterns and aging baby boomers. Europe follows closely, with countries like Germany and the UK implementing robust screening and surgical programs. In Asia-Pacific, the market is expanding rapidly due to urbanization, increasing disposable incomes, and greater access to healthcare services. Emerging markets such as India and China are witnessing a steady rise in cases, driven by shifts in diet and lifestyle. These regions are also investing in hospital infrastructure and medical training, leading to improved diagnostic and treatment capabilities. Latin America and the Middle East are nascent markets with rising awareness and increasing investments in gastrointestinal care. Across all regions, the demand for personalized and value-based care models is influencing treatment patterns and reimbursement strategies.

What Are the Key Factors Driving Market Growth?

The growth in the diverticulitis disease market is driven by several factors, including the rising prevalence of gastrointestinal disorders associated with aging populations and dietary changes, particularly in urbanized areas. Advances in diagnostic imaging technologies and increased access to colonoscopy screenings are enabling earlier and more accurate diagnoses, expanding the base of treated patients. Changes in clinical guidelines emphasizing conservative management have increased the role of pharmaceuticals, creating opportunities for drug manufacturers. Simultaneously, the expansion of minimally invasive surgical techniques has boosted the demand for surgical instruments and robotic systems. Growing patient awareness, combined with greater health literacy and demand for outpatient care, is reshaping the way diverticulitis is managed across healthcare settings. The development of new pharmaceutical agents targeting inflammation and gut microbiota modulation is also fueling innovation in the treatment pipeline. Moreover, the integration of gastrointestinal care into broader chronic disease management frameworks is reinforcing its strategic importance within global healthcare systems.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Medications Treatment segment, which is expected to reach US$666.1 Million by 2030 with a CAGR of a 5.8%. The Surgery Treatment segment is also set to grow at 5.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $489.1 Million in 2024, and China, forecasted to grow at an impressive 10.3% CAGR to reach $542.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Diverticulitis Disease Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Diverticulitis Disease Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Diverticulitis Disease Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Allergan (AbbVie), AstraZeneca, Bausch Health Companies, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Diverticulitis Disease market report include:

• Abbott Laboratories
• Allergan (AbbVie)
• AstraZeneca
• Bausch Health Companies
• Baxter International
• Bristol-Myers Squibb
• Ferring Pharmaceuticals
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Medtronic
• Mylan (Viatris)
• Novartis
• Pfizer
• Roche
• Sanofi
• Sandoz (Novartis)
• Takeda Pharmaceutical
• Teva Pharmaceutical
• UCB

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.